港股创新药ETF（159567）涨2.24%，成交额11.42亿元

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed up 2.24% on October 15, with a trading volume of 1.142 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 14, 2024, the fund's latest share count was 8.248 billion, with a total size of 6.967 billion yuan, reflecting a year-to-date increase of 1986.11% in shares and 1744.01% in size [1] Performance Metrics - The fund's performance benchmark is the National Index of Hong Kong Innovative Drugs, adjusted for valuation exchange rates [1] - The fund manager, Ma Jun, has achieved a return of 77.66% since taking over management on January 3, 2024 [2] Liquidity Analysis - Over the last 20 trading days, the ETF has accumulated a trading volume of 30.689 billion yuan, with an average daily trading amount of 1.534 billion yuan [1] - Year-to-date, the ETF has seen a total trading volume of 220.734 billion yuan over 188 trading days, averaging 1.174 billion yuan per day [1] Holdings Overview - Major holdings in the ETF include: - Innovent Biologics (9.52% holding, 2.60 billion yuan market value) - WuXi Biologics (9.47% holding, 2.58 billion yuan market value) - BeiGene (8.73% holding, 2.38 billion yuan market value) - CanSino Biologics (7.62% holding, 2.08 billion yuan market value) - China National Pharmaceutical Group (7.17% holding, 1.96 billion yuan market value) [2]